Athersys Company Profile (NASDAQ:ATHX)

About Athersys (NASDAQ:ATHX)

Athersys logoAthersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. In the neurological area, the Company evaluated in a completed Phase II trial, the potential for MultiStem treatment of patients with a history of neurological damage from an ischemic stroke. The Company initiated a Phase II clinical study in the United States for the administration of MultiStem cell therapy to patients with a history of an acute myocardial infarction, or AMI.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ATHX
  • CUSIP: N/A
  • Web:
  • Market Cap: $181.45 million
  • Outstanding Shares: 111,316,000
Average Prices:
  • 50 Day Moving Avg: $1.56
  • 200 Day Moving Avg: $1.41
  • 52 Week Range: $1.02 - $2.30
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.64
  • P/E Growth: -0.22
Sales & Book Value:
  • Annual Revenue: $3.36 million
  • Price / Sales: 54.33
  • Book Value: $0.26 per share
  • Price / Book: 6.31
  • EBIDTA: ($28,340,000.00)
  • Net Margins: -765.65%
  • Return on Equity: -135.04%
  • Return on Assets: -95.38%
  • Current Ratio: 4.15%
  • Quick Ratio: 4.15%
  • Average Volume: 622,356 shs.
  • Beta: -0.19
  • Short Ratio: 9.7
Frequently Asked Questions for Athersys (NASDAQ:ATHX)

What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) released its earnings results on Tuesday, May, 9th. The company reported ($0.06) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.07) by $0.01. The company earned $1.50 million during the quarter, compared to analysts' expectations of $0.45 million. Athersys had a negative net margin of 765.65% and a negative return on equity of 135.04%. The business's revenue was down 90.3% on a year-over-year basis. During the same quarter last year, the business earned $0.06 EPS. View Athersys' Earnings History.

When will Athersys make its next earnings announcement?

Athersys is scheduled to release their next quarterly earnings announcement on Wednesday, August, 9th 2017. View Earnings Estimates for Athersys.

Where is Athersys' stock going? Where will Athersys' stock price be in 2017?

3 brokers have issued twelve-month target prices for Athersys' shares. Their forecasts range from $7.00 to $9.00. On average, they expect Athersys' share price to reach $8.00 in the next twelve months. View Analyst Ratings for Athersys.

What are analysts saying about Athersys stock?

Here are some recent quotes from research analysts about Athersys stock:

  • 1. Maxim Group analysts commented, "Athersys spent $5.6M in the quarter and ended the period with $32M in cash at the end of the period (which includes $21M from a capital raise in February). This capital should support the company for the next year. Lonza: Athersys manufacturing partner completed a manufacturing review that has now paved the way for product to be supplied for pivotal trials (including Healio’s Treasure trial). Partnering: Looking for partners now for MultiStem." (5/10/2017)
  • 2. According to Zacks Investment Research, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived ``off the shelf'' stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. " (3/14/2017)
  • 3. Needham & Company LLC analysts commented, "Athersys is developing MultiStem, an off-the-shelf cell therapy that promotes tissue repair. The lead indication is ischemic stroke. Existing stroke treatments, which focus on removing the offending blood clot, can only be used in a short window of time, but MultiStem has shown efficacy in a longer time window (24-36 hours) and can thus address far more patients. Athersys' Japanese partner Healios will start a 220-patient pivotal trial shortly. Data is expected in mid-2018. While there is some controversy around the Phase II data, we believe the trial has a favorable risk:reward in what we see as a blockbuster opportunity. Initiate at Buy with a $7 price target." (2/7/2017)

Who are some of Athersys' key competitors?

Who are Athersys' key executives?

Athersys' management team includes the folowing people:

  • Gil Van Bokkelen Ph.D., Chairman of the Board, Chief Executive Officer
  • William Lehmann Jr, President, Chief Operating Officer
  • John J. Harrington Ph.D., Executive Vice President, Chief Scientific Officer, Director
  • Robert J. Deans Ph.D., Executive Vice President - Regenerative Medicine
  • Laura K. Campbell CPA, Vice President - Finance
  • Lee E. Babiss Ph.D., Lead Independent Director
  • Ismail Kola, Independent Director
  • Lorin Jeffry Randall, Independent Director
  • Jack L. Wyszomierski, Independent Director

Who owns Athersys stock?

Athersys' stock is owned by many different of institutional and retail investors. Top institutional investors include NEXT Financial Group Inc (0.09%). Company insiders that own Athersys stock include Bokkelen Gil Van, Ismail Kola, John J Harrington, Laura K Campbell, William Lehmann Jr and William Lehmann, Jr. View Institutional Ownership Trends for Athersys.

Who bought Athersys stock? Who is buying Athersys stock?

Athersys' stock was bought by a variety of institutional investors in the last quarter, including NEXT Financial Group Inc. Company insiders that have bought Athersys stock in the last two years include Ismail Kola and Laura K Campbell. View Insider Buying and Selling for Athersys.

How do I buy Athersys stock?

Shares of Athersys can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Athersys' stock price today?

One share of Athersys stock can currently be purchased for approximately $1.64.

MarketBeat Community Rating for Athersys (NASDAQ ATHX)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  100 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  148
MarketBeat's community ratings are surveys of what our community members think about Athersys and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Athersys (NASDAQ:ATHX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.00 (387.80% upside)

Analysts' Ratings History for Athersys (NASDAQ:ATHX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/16/2017Maxim GroupSet Price TargetBuy$9.00MediumView Rating Details
3/28/2017William BlairReiterated RatingOutperformHighView Rating Details
2/7/2017Needham & Company LLCInitiated CoverageBuy$7.00N/AView Rating Details
1/10/2016WBB SecuritiesReiterated RatingBuy$9.00N/AView Rating Details
(Data available from 7/22/2015 forward)


Earnings History for Athersys (NASDAQ:ATHX)
Earnings by Quarter for Athersys (NASDAQ:ATHX)
Earnings History by Quarter for Athersys (NASDAQ ATHX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017($0.06)N/AView Earnings Details
5/9/2017Q1 2017($0.07)($0.06)$0.45 million$1.50 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.08)($0.10)$0.45 million$0.98 millionViewListenView Earnings Details
11/9/2016Q3 2016($0.10)($0.07)$0.60 million$0.31 millionViewListenView Earnings Details
8/9/2016Q216($0.10)($0.08)$0.32 million$0.60 millionViewN/AView Earnings Details
5/5/2016Q1($0.08)$0.06$1.85 million$15.45 millionViewN/AView Earnings Details
3/10/2016Q4($0.09)$0.04$3.72 million$10.61 millionViewListenView Earnings Details
11/5/2015Q315($0.07)($0.08)$1.75 million$0.40 millionViewListenView Earnings Details
8/6/2015Q2($0.08)$0.02$2.66 million$0.22 millionViewN/AView Earnings Details
5/11/2015Q115($0.07)($0.16)$2.01 million$0.73 millionViewListenView Earnings Details
3/12/2015Q414($0.09)($0.08)$0.50 million$0.24 millionViewN/AView Earnings Details
11/10/2014Q314($0.09)($0.11)$0.54 million$0.29 millionViewN/AView Earnings Details
8/11/2014Q214($0.09)($0.06)$0.70 million$0.40 millionViewN/AView Earnings Details
5/8/2014Q114($0.10)($0.09)$0.66 million$0.71 millionViewN/AView Earnings Details
3/13/2014Q413($0.11)($0.15)$1.81 million$0.92 millionViewN/AView Earnings Details
11/14/2013Q3($0.12)($0.10)$0.49 million$0.62 millionViewListenView Earnings Details
8/13/2013Q2 2013($0.12)($0.11)$390.00 million$0.57 millionViewN/AView Earnings Details
5/14/2013Q1 2013($0.11)($0.18)$1.58 million$0.33 millionViewN/AView Earnings Details
11/8/2012Q312($0.13)($0.12)$2.51 million$1.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Athersys (NASDAQ:ATHX)
2017 EPS Consensus Estimate: ($0.27)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.07)($0.07)($0.07)
Q2 20172($0.07)($0.06)($0.07)
Q3 20172($0.07)($0.06)($0.07)
Q4 20172($0.07)($0.06)($0.07)
(Data provided by Zacks Investment Research)


Dividend History for Athersys (NASDAQ:ATHX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Athersys (NASDAQ:ATHX)
Insider Ownership Percentage: 9.40%
Institutional Ownership Percentage: 17.75%
Insider Trades by Quarter for Athersys (NASDAQ:ATHX)
Institutional Ownership by Quarter for Athersys (NASDAQ:ATHX)
Insider Trades by Quarter for Athersys (NASDAQ:ATHX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/16/2017John J HarringtonEVPSell36,000$1.45$52,200.00View SEC Filing  
2/1/2017Ismail KolaDirectorBuy15,000$1.01$15,150.00View SEC Filing  
2/1/2017Laura K CampbellInsiderBuy20,000$1.01$20,200.00View SEC Filing  
12/19/2016William Lehmann JrInsiderSell3,000$1.60$4,800.00View SEC Filing  
12/16/2016John J HarringtonEVPSell15,000$1.60$24,000.00View SEC Filing  
9/19/2016William Lehmann JrInsiderSell3,000$1.96$5,880.00View SEC Filing  
9/16/2016John J HarringtonEVPSell15,000$1.96$29,400.00View SEC Filing  
6/21/2016William Lehmann JrCOOSell25,000$2.17$54,250.00View SEC Filing  
3/21/2016William Lehmann JrCOOSell25,000$2.41$60,250.00View SEC Filing  
12/21/2015William Lehmann, Jr.COOSell25,000$1.03$25,750.00View SEC Filing  
9/21/2015Bokkelen Gil VanCEOSell9,500$1.36$12,920.00View SEC Filing  
9/21/2015John J. HarringtonEVPSell8,150$1.36$11,084.00View SEC Filing  
9/21/2015William Lehmann, Jr.COOSell25,000$1.36$34,000.00View SEC Filing  
6/22/2015William Lehmann JrCOOSell25,000$1.21$30,250.00View SEC Filing  
6/19/2015John J HarringtonInsiderSell8,150$1.23$10,024.50View SEC Filing  
6/19/2015Robert J DeansEVPSell5,080$1.23$6,248.40View SEC Filing  
6/9/2015Kenneth H TraubDirectorBuy30,000$1.27$38,100.00View SEC Filing  
3/20/2015William Lehmann JrCOOSell25,000$3.14$78,500.00View SEC Filing  
3/19/2015Bokkelen Gil VanCEOSell9,500$3.10$29,450.00View SEC Filing  
3/19/2015Robert J DeansEVPSell5,080$3.10$15,748.00View SEC Filing  
12/19/2014Bokkelen Gil VanCEOSell9,500$1.29$12,255.00View SEC Filing  
12/19/2014Robert J DeansEVPSell5,080$1.28$6,502.40View SEC Filing  
12/19/2014William Lehmann JrCOOSell30,000$1.29$38,700.00View SEC Filing  
9/24/2014Kenneth H TraubDirectorBuy30,000$1.39$41,700.00View SEC Filing  
9/22/2014William Lehmann JrCOOSell30,000$1.40$42,000.00View SEC Filing  
9/19/2014Bokkelen Gil VanCEOSell9,500$1.41$13,395.00View SEC Filing  
9/19/2014John J HarringtonInsiderSell8,150$1.41$11,491.50View SEC Filing  
9/19/2014Robert J DeansEVPSell5,080$1.41$7,162.80View SEC Filing  
8/18/2014Lorin RandallDirectorSell15,000$1.54$23,100.00View SEC Filing  
6/20/2014William Lehmann JrCOOSell12,000$1.58$18,960.00View SEC Filing  
6/19/2014Bokkelen Gil VanCEOSell9,500$1.63$15,485.00View SEC Filing  
6/19/2014John J HarringtonInsiderSell8,150$1.63$13,284.50View SEC Filing  
6/19/2014Robert J DeansEVPSell5,080$1.63$8,280.40View SEC Filing  
6/19/2014William Lehmann JrCOOSell13,000$1.62$21,060.00View SEC Filing  
3/20/2014William Lehmann JrCOOSell25,000$3.62$90,500.00View SEC Filing  
3/18/2014Bokkelen Gil VanCEOSell9,500$3.54$33,630.00View SEC Filing  
3/18/2014John J HarringtonInsiderSell8,150$3.54$28,851.00View SEC Filing  
3/18/2014Robert J DeansEVPSell5,080$3.54$17,983.20View SEC Filing  
12/20/2013William Lehmann JrCOOSell25,000$2.13$53,250.00View SEC Filing  
12/11/2013Kenneth H TraubDirectorBuy20,000$1.94$38,800.00View SEC Filing  
9/20/2013John J HarringtonInsiderSell30,000$1.82$54,600.00View SEC Filing  
9/20/2013William Lehmann JrCOOSell12,000$1.83$21,960.00View SEC Filing  
11/28/2012Laura K CampbellVPBuy10,000$1.01$10,100.00View SEC Filing  
11/15/2012Robert J DeansEVPBuy3,500$0.99$3,465.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Athersys (NASDAQ:ATHX)
Latest Headlines for Athersys (NASDAQ:ATHX)
DateHeadline logoAthersys to Host Second Quarter Financial Results Call - GlobeNewswire (press release) - July 10 at 4:10 PM logoAthersys to Host Second Quarter Financial Results Call - July 10 at 4:10 PM logo Athersys, Inc. (NASDAQ:ATHX) Receives Consensus Recommendation of "Strong Buy" from Brokerages - July 10 at 2:30 PM logoETFs with exposure to Athersys, Inc. : July 7, 2017 - July 8 at 7:02 AM logoAthersys And Aurinia Target Human And Animal Health - Seeking Alpha - June 27 at 3:50 PM logo Athersys, Inc. (ATHX) Receives Consensus Recommendation of "Strong Buy" from Brokerages - June 23 at 8:56 AM logoAthersys, Inc. (ATHX) EVP John J. Harrington Sells 36,000 Shares - June 19 at 7:57 PM logoWhy Athersys, Inc. (ATHX) Could Be Positioned for a Surge - Nasdaq - June 9 at 2:28 AM logoWhy Athersys, Inc. (ATHX) Could Be Positioned for a Surge - June 8 at 4:24 PM logoZacks: Athersys, Inc. (ATHX) Receives Consensus Recommendation of "Strong Buy" from Analysts - June 8 at 8:16 AM logoUpcoming Short- And Long-Term Catalysts For Athersys - Seeking Alpha - May 31 at 3:41 PM logoZacks: Athersys, Inc. (ATHX) Given Average Rating of "Strong Buy" by Analysts - May 24 at 4:30 PM logoMaxim Group Reiterates $9.00 Price Target for Athersys, Inc. (ATHX) - May 17 at 7:10 PM logoAthersys Poised For Lucrative Stem Cell Stroke Partnership This Year - May 16 at 12:30 PM logoETFs with exposure to Athersys, Inc. : May 15, 2017 - May 15 at 4:11 PM logoAthersys, Inc. (ATHX) Given "Buy" Rating at Maxim Group - May 14 at 4:00 PM logoAthersys, Inc. :ATHX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 - May 12 at 4:14 PM logoAthersys, Inc. (ATHX) to Post Q2 2017 Earnings of ($0.06) Per Share, William Blair Forecasts - May 12 at 10:40 AM logoAthersys beats by $0.01, beats on revenue - May 11 at 9:11 PM logoEquities Analysts Issue Forecasts for Athersys, Inc.'s FY2019 Earnings (ATHX) - May 11 at 3:20 PM logoEdited Transcript of ATHX earnings conference call or presentation 9-May-17 8:30pm GMT - May 10 at 8:55 PM logoAthersys, Inc. (ATHX) Posts Earnings Results, Beats Expectations By $0.01 EPS - May 9 at 9:42 PM logoAthersys Reports First Quarter 2017 Results - May 9 at 8:44 PM logoAthersys, Inc. (ATHX) Downgraded by Zacks Investment Research - May 9 at 4:38 PM logoAthersys, Inc. (ATHX) - May 8 at 8:38 PM logoAthersys, Inc. (ATHX) Scheduled to Post Quarterly Earnings on Tuesday - May 7 at 7:12 AM logo Analysts Set $9.00 Target Price for Athersys, Inc. (ATHX) - May 5 at 9:18 AM logoAthersys (ATHX) Given Daily Coverage Optimism Score of 0.03 - May 4 at 4:22 PM logoAthersys (ATHX) Earning Positive Media Coverage, Report Shows - May 1 at 12:38 PM logoShort Interest in Athersys, Inc. (ATHX) Grows By 129.9% - April 27 at 7:06 AM logoAthersys (ATHX) Earns Daily Coverage Optimism Score of 0.22 - April 26 at 4:52 PM logoAthersys (ATHX) Given Daily News Sentiment Rating of 0.17 - April 23 at 10:16 AM logo Athersys, Inc. (ATHX) Given $9.00 Average Target Price by Analysts - April 20 at 11:25 AM logoAthersys (ATHX) Given News Sentiment Rating of 0.16 - April 20 at 8:29 AM logoAthersys: Initiating Coverage With Buy Rating And Price Target Of $8 - April 19 at 4:00 PM logoShort Interest in Athersys, Inc. (ATHX) Decreases By 11.4% - April 18 at 12:54 PM logoAthersys (ATHX) Earns Daily News Sentiment Rating of 0.24 - April 17 at 4:04 PM logoAthersys to Host First Quarter Financial Results Call - April 10 at 3:40 PM logoZacks: Analysts Set $9.00 Price Target for Athersys, Inc. (ATHX) - April 5 at 9:31 AM logoWilliam Blair Reaffirms "Outperform" Rating for Athersys, Inc. (ATHX) - April 3 at 8:32 AM logoHere's What Might Be Pushing Up Shares of Athersys, Inc. Today - March 31 at 3:49 PM logoCan the Rally in Athersys (ATHX) Shares Continue? - March 31 at 3:49 PM logoAthersys, Inc. (ATHX) to Post Q1 2017 Earnings of ($0.07) Per Share, William Blair Forecasts - March 31 at 12:05 PM logoIs the Options Market Predicting a Spike in Athersys (ATHX) Stock? - March 30 at 4:07 PM logoTonix Pharmaceuticals and Athersys Advance as FDA Clinical Trials Move Forward - March 30 at 4:07 PM logoAthersys to Present at Needham Healthcare Conference on April 4 - March 29 at 8:53 PM logoAthersys (ATHX) Stock Rallies as William Blair Initiates Coverage - March 29 at 8:53 PM logoAthersys, Inc. (ATHX) Now Covered by Analysts at William Blair - March 28 at 6:42 PM logoAthersys, Inc. (ATHX) Given a $9.00 Price Target by Maxim Group Analysts - March 21 at 3:40 PM logoBrokerages Expect Athersys, Inc. (ATHX) to Post ($0.06) EPS - March 21 at 11:52 AM



Athersys (ATHX) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by Staff